01879nas a2200217   4500000000100000008004100001260001600042653002100058653002800079653002200107653002600129653003300155653003200188100001200220245007700232856015300309300000900462490000600471520117000477022001401647       2024                            d  bElsevier BV10aDrug repurposing10aArtificial Intelligence10aVirtual screening10aTarget identification10aEmerging infectious diseases10aStructure-based drug design1 aSingh A00aArtificial intelligence for drug repurposing against infectious diseases  uhttps://www.sciencedirect.com/science/article/pii/S2949747724000290/pdfft?md5=061eb4d8766a2284afb22976a6d28b51&pid=1-s2.0-S2949747724000290-main.pdf  a1-140 v23 a<p>Traditional drug discovery struggles to keep pace with the ever-evolving threat of infectious diseases. New viruses and antibiotic-resistant bacteria, all demand rapid solutions. Artificial Intelligence (AI) offers a promising path forward through accelerated drug repurposing. AI allows researchers to analyze massive datasets, revealing hidden connections between existing drugs, disease targets, and potential treatments. This approach boasts several advantages. First, repurposing existing drugs leverages established safety data and reduces development time and costs. Second, AI can broaden the search for effective therapies by identifying unexpected connections between drugs and potential new targets. Finally, AI can help mitigate limitations by predicting and minimizing side effects, optimizing drugs for repurposing, and navigating intellectual property hurdles. The article explores specific AI strategies like virtual screening, target identification, structure base drug design and natural language processing. Real-world examples highlight the potential of AI-driven drug repurposing in discovering new treatments for infectious diseases.</p>
  a2949-7477